| Year |
Citation |
Score |
| 2021 |
Koneru B, Farooqi A, Nguyen TH, Chen WH, Hindle A, Eslinger C, Makena MR, Burrow TA, Wilson J, Smith A, Pilla Reddy V, Cadogan E, Durant ST, Reynolds CP. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156. Science Translational Medicine. 13. PMID 34408079 DOI: 10.1126/scitranslmed.abd5750 |
0.303 |
|
| 2020 |
Wei SJ, Nguyen TH, Yang IH, Mook DG, Makena MR, Verlekar D, Hindle A, Martinez GM, Yang S, Shimada H, Reynolds CP, Kang MH. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death & Disease. 11: 368. PMID 32409685 DOI: 10.1038/S41419-020-2563-4 |
0.358 |
|
| 2020 |
Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, Modi A, Rokita JL, Urias E, Hindle A, Davidson H, Mccoy K, Nance J, Yazdani V, Irwin MS, ... ... Reynolds CP, et al. Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Research. PMID 32291317 DOI: 10.1158/0008-5472.Can-19-3068 |
0.356 |
|
| 2020 |
Wei SJ, Nguyen TH, Mook DG, Makena MR, Verlekar D, Hindle A, Martinez G, Yang S, Shimada H, Reynolds CP, Kang MH. Abstract 1293: MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma Cancer Research. 80: 1293-1293. DOI: 10.1158/1538-7445.Am2020-1293 |
0.363 |
|
| 2019 |
Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Kai Lim H, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, et al. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature Communications. 10: 5428. PMID 31780656 DOI: 10.1038/S41467-019-13315-X |
0.373 |
|
| 2019 |
Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, ... ... Reynolds CP, et al. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports. 29: 1675-1689.e9. PMID 31693904 DOI: 10.1016/J.Celrep.2019.09.071 |
0.382 |
|
| 2019 |
Reynolds CP, Nguyen TH, Koneru B, Wei SJ, Chen WH, Makena MR, Urias E, Kang MH. Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2-expressing neuroblastoma preclinical models. Molecular Cancer Therapeutics. PMID 31484706 DOI: 10.1158/1535-7163.Mct-19-0385 |
0.353 |
|
| 2019 |
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, ... ... Reynolds CP, et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering. 3: 264-280. PMID 30952988 DOI: 10.1038/S41551-019-0385-4 |
0.317 |
|
| 2019 |
Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics : Targets & Therapy. 13: 1-12. PMID 30613134 DOI: 10.2147/Btt.S114530 |
0.364 |
|
| 2019 |
Heisey DA, Lochmann T, Calbert M, Ghotra M, Maves YK, Boikos S, Benes C, Reynolds CP, Faber A. Abstract 4329: Pharmaceutical means of targeting the fusion oncogene EWS-FLI1 in the Ewing family of tumors Cancer Research. 79: 4329-4329. DOI: 10.1158/1538-7445.Am2019-4329 |
0.369 |
|
| 2019 |
Zapata C, Coku J, Liu K, Vu A, Goutnik M, Reynolds CP, Goldsmith K, Hogarty M. Abstract 2504: Predictive biomarkers for Bcl2-inhibitor use in neuroblastoma Cancer Research. 79: 2504-2504. DOI: 10.1158/1538-7445.Am2019-2504 |
0.349 |
|
| 2018 |
Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Bence Lin A, P Beckmann R, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, ... ... Reynolds CP, et al. Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30563935 DOI: 10.1158/1078-0432.Ccr-18-2728 |
0.401 |
|
| 2018 |
Song MM, Makena MR, Hindle A, Koneru B, Nguyen TH, Verlekar DU, Cho H, Maurer BJ, Kang MH, Reynolds CP. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anti-Cancer Drugs. PMID 30272587 DOI: 10.1097/Cad.0000000000000696 |
0.357 |
|
| 2018 |
Makena MR, Cho HE, Nguyen TH, Koneru B, Verlekar DU, Hindle A, Kang MH, Reynolds CP. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. Pediatric Blood & Cancer. e27447. PMID 30251395 DOI: 10.1002/Pbc.27447 |
0.36 |
|
| 2018 |
Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Science Translational Medicine. 10. PMID 29769286 DOI: 10.1126/Scitranslmed.Aao4680 |
0.374 |
|
| 2018 |
Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, et al. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood & Cancer. e27023. PMID 29603591 DOI: 10.1002/Pbc.27023 |
0.313 |
|
| 2018 |
Vad N, Wang D, Cho H, Verlekar D, Linch C, Reynolds CP, Kang M, Maurer BJ. Abstract 2885: Dihydroceramide increase precedes golgi dispersal, pro-survival autophagy, ER stress, and UPR in fenretinide + safingol treated neuroblastoma cells Cancer Research. 78: 2885-2885. DOI: 10.1158/1538-7445.Am2018-2885 |
0.354 |
|
| 2018 |
Cole KA, Houghton PJ, Kurmasheva RT, Gorlick R, Kolb EA, Kang M, Reynolds CP, Li X, Lindsay H, Erickson SW, Guo Y, Teicher BA, Smith MA, Maris JM. Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B13 |
0.433 |
|
| 2017 |
Kurmasheva RT, Kurmashev D, Reynolds CP, Kang M, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. PMID 28921800 DOI: 10.1002/Pbc.26825 |
0.328 |
|
| 2017 |
Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, ... Reynolds CP, et al. A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget. 8: 50489-50499. PMID 28881577 DOI: 10.18632/Oncotarget.9929 |
0.391 |
|
| 2017 |
Li W, Zhang Y, Reynolds CP, Pappas D. Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia using the Human Transferrin Receptor as a Capture Target. Analytical Chemistry. PMID 28656755 DOI: 10.1021/Acs.Analchem.7B00377 |
0.306 |
|
| 2017 |
Dagg RA, Pickett HA, Neumann AA, Napier CE, Henson JD, Teber ET, Arthur JW, Reynolds CP, Murray J, Haber M, Sobinoff AP, Lau LMS, Reddel RR. Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Reports. 19: 2544-2556. PMID 28636942 DOI: 10.1016/J.Celrep.2017.05.087 |
0.383 |
|
| 2017 |
Cooper JP, Reynolds CP, Cho H, Kang MH. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. Experimental Biology and Medicine (Maywood, N.J.). 1535370217706952. PMID 28429653 DOI: 10.1177/1535370217706952 |
0.324 |
|
| 2017 |
Mohrbacher A, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman E, Maurer BJ. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: a California Cancer Consortium Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420721 DOI: 10.1158/1078-0432.Ccr-17-0234 |
0.319 |
|
| 2017 |
Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Scientific Data. 4: 170033. PMID 28350380 DOI: 10.1038/Sdata.2017.33 |
0.321 |
|
| 2017 |
Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. International Journal of Cancer. PMID 28340497 DOI: 10.1002/Ijc.30706 |
0.374 |
|
| 2017 |
Makena MR, Koneru B, Nguyen TH, Kang MH, Reynolds CP. Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. Molecular Cancer Therapeutics. PMID 28119491 DOI: 10.1158/1535-7163.Mct-16-0749 |
0.379 |
|
| 2017 |
Harker-Murray PD, Meyer WH, Leavey P, Kang MH, Cho H, Adiwijaya BS, Fitzgerald JB, Pipas JM, Drummond DC, Reynolds CP. Abstract CT146: Plasma pharmacokinetics of liposomal irinotecan (nal-IRI) in pediatric oncology patients with recurrent or refractory solid tumors: South Plains Oncology Consortium Study 2012-001 Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct146 |
0.357 |
|
| 2017 |
Makena MR, Koneru B, Kang MH, Reynolds CP. Abstract 2038: Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies Cancer Research. 77: 2038-2038. DOI: 10.1158/1538-7445.Am2017-2038 |
0.403 |
|
| 2016 |
Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. PMID 27786412 DOI: 10.1002/Pbc.26304 |
0.416 |
|
| 2016 |
Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood & Cancer. PMID 27650817 DOI: 10.1002/Pbc.26263 |
0.312 |
|
| 2016 |
Chen NE, Maldonado V, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP. Reactive oxygen species mediates the synergistic activity of fenretinide combined with the microtubule Inhibitor ABT-751 against multi-drug resistant recurrent neuroblastoma xenografts. Molecular Cancer Therapeutics. PMID 27530131 DOI: 10.1158/1535-7163.Mct-16-0156 |
0.375 |
|
| 2016 |
Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, et al. Evaluation of Alternative In Vivo Drug Screening Methodology: single mouse analysis. Cancer Research. PMID 27496711 DOI: 10.1158/0008-5472.Can-16-0122 |
0.365 |
|
| 2016 |
Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. PMID 27238606 DOI: 10.1002/Pbc.26064 |
0.361 |
|
| 2016 |
Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 63: 443-50. PMID 26797892 DOI: 10.1002/Pbc.25826 |
0.477 |
|
| 2016 |
Coku J, Scadden EO, Liu K, Vu A, Booth DM, Chen M, Kim S, Reynolds CP, Hajnóczky G, Hogarty MD. Abstract 2459: Chemotherapy resistance in pediatric neuroblastoma is associated with reduced ER-mitochondria tethering Cancer Research. 76: 2459-2459. DOI: 10.1158/1538-7445.Am2016-2459 |
0.373 |
|
| 2015 |
Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, et al. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatric Blood & Cancer. PMID 26398108 DOI: 10.1002/Pbc.25727 |
0.331 |
|
| 2015 |
Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatric Blood & Cancer. PMID 26154614 DOI: 10.1002/Pbc.25611 |
0.459 |
|
| 2015 |
Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood & Cancer. 62: 1739-46. PMID 26153194 DOI: 10.1002/Pbc.25594 |
0.345 |
|
| 2015 |
Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP. Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Experimental Cell Research. 334: 78-89. PMID 25845499 DOI: 10.1016/J.Yexcr.2015.03.024 |
0.328 |
|
| 2015 |
Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1139-50. PMID 25733708 DOI: 10.1158/1078-0432.Ccr-14-1882 |
0.375 |
|
| 2015 |
Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunology, Immunotherapy : Cii. 64: 621-34. PMID 25711293 DOI: 10.1007/S00262-015-1669-5 |
0.306 |
|
| 2015 |
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 819-32. PMID 25500058 DOI: 10.1158/1078-0432.Ccr-14-2572 |
0.413 |
|
| 2015 |
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 62: 1106-9. PMID 25407467 DOI: 10.1002/Pbc.25329 |
0.442 |
|
| 2015 |
Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood & Cancer. 62: 91-8. PMID 25263539 DOI: 10.1002/Pbc.25201 |
0.443 |
|
| 2015 |
Song MM, Makena MR, Hindle A, Koneru B, Nguyen TH, Cho H, Maurer BJ, Kang MH, Reynolds CP. Abstract 2616: Comparison of the cytotoxicity and increase of reactive oxygen species and dihydroceramides of fenretinide to its major metabolites (4-oxo- and 4-methoxyphenyl fenretinide) in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines Cancer Research. 75: 2616-2616. DOI: 10.1158/1538-7445.Am2015-2616 |
0.333 |
|
| 2015 |
Zhang Y, Stastny V, Papari-Zareei M, Davidson H, Gao B, Timmons B, Yan J, Reynolds CP, Minna JD, Gazdar AF. Abstract 225: Assessing and enriching human tumor cell content in patient-derived cancer xenografts and co-cultures Cancer Research. 75: 225-225. DOI: 10.1158/1538-7445.Am2015-225 |
0.359 |
|
| 2014 |
Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1972-9. PMID 25131802 DOI: 10.1002/Pbc.25175 |
0.439 |
|
| 2014 |
Ryu Y, Hall CP, Reynolds CP, Kang MH. Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. Experimental Biology and Medicine (Maywood, N.J.). 239: 1390-402. PMID 24951472 DOI: 10.1177/1535370214538745 |
0.343 |
|
| 2014 |
Farooqi AS, Dagg RA, Choi LM, Shay JW, Reynolds CP, Lau LM. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. Journal of Neuro-Oncology. 119: 17-26. PMID 24792489 DOI: 10.1007/S11060-014-1456-8 |
0.374 |
|
| 2014 |
Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1493-6. PMID 24664981 DOI: 10.1002/Pbc.25026 |
0.453 |
|
| 2014 |
Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 1486-9. PMID 24623675 DOI: 10.1002/Pbc.24989 |
0.371 |
|
| 2014 |
Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 61: 922-4. PMID 24166988 DOI: 10.1002/Pbc.24800 |
0.42 |
|
| 2014 |
Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61: 245-52. PMID 24038993 DOI: 10.1002/Pbc.24724 |
0.462 |
|
| 2014 |
Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61: 158-64. PMID 23956067 DOI: 10.1002/Pbc.24616 |
0.474 |
|
| 2014 |
Maurer BJ, Bender JLG, Kang MH, Villablanca J, Wei D, Groshen SG, Yang S, Czarnecki S, Granger MP, Katzenstein HM, Weiss BD, Matthay KK, Reynolds CP, Marachelian A. Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial. Journal of Clinical Oncology. 32: 10071-10071. DOI: 10.1200/Jco.2014.32.15_Suppl.10071 |
0.33 |
|
| 2014 |
Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith MA, Seeger R, Reynolds CP, Maris JM, Park JR. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. Journal of Clinical Oncology. 32: 10044-10044. DOI: 10.1200/Jco.2014.32.15_Suppl.10044 |
0.303 |
|
| 2014 |
Kang MH, Song MM, Makena M, Lee J, Hall CP, Hindle A, Ko W, Paz N, Fitzgerald J, Drummond DC, Triche TJ, Reynolds CP. Abstract 3972: Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and highSLFN11expression Cancer Research. 74: 3972-3972. DOI: 10.1158/1538-7445.Am2014-3972 |
0.433 |
|
| 2014 |
Seidel D, Shibina A, Reynolds CP, Wels WS, Huebener N, Lode HN. Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model Cancer Research. 74: 2808-2808. DOI: 10.1158/1538-7445.Am2014-2808 |
0.354 |
|
| 2013 |
May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. Plos One. 8: e80060. PMID 24312454 DOI: 10.1371/Journal.Pone.0080060 |
0.4 |
|
| 2013 |
Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 1860-7. PMID 23798344 DOI: 10.1002/Pbc.24647 |
0.383 |
|
| 2013 |
Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 1325-32. PMID 23553917 DOI: 10.1002/Pbc.24517 |
0.445 |
|
| 2013 |
Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 783-90. PMID 23335050 DOI: 10.1002/Pbc.24368 |
0.349 |
|
| 2013 |
Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 60: E42-5. PMID 23303741 DOI: 10.1002/Pbc.24451 |
0.417 |
|
| 2013 |
Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics. 45: 12-7. PMID 23202128 DOI: 10.1038/Ng.2493 |
0.319 |
|
| 2013 |
Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Journal of Molecular Medicine (Berlin, Germany). 91: 459-72. PMID 23052481 DOI: 10.1007/S00109-012-0958-0 |
0.389 |
|
| 2013 |
Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 60: 791-8. PMID 23002019 DOI: 10.1002/Pbc.24301 |
0.397 |
|
| 2013 |
Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 60: 633-41. PMID 22753001 DOI: 10.1002/Pbc.24235 |
0.348 |
|
| 2013 |
Woodburn T, Hall HA, White K, Calderon R, Blaydes R, Farooqi A, Hogarty M, Mosse Y, Maris J, Erdreich-Epstein A, Miller B, Reynolds CP. Abstract 2786: Establishing validated pediatric cancer cell lines and direct xenografts from post-mortem samples. Cancer Research. 73: 2786-2786. DOI: 10.1158/1538-7445.Am2013-2786 |
0.407 |
|
| 2013 |
Houghton PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Smith MA. Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel. Cancer Research. 73: 2754-2754. DOI: 10.1158/1538-7445.Am2013-2754 |
0.383 |
|
| 2012 |
Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, Hogarty MD. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Research. 72: 2565-77. PMID 22589275 DOI: 10.1158/0008-5472.Can-11-3603 |
0.394 |
|
| 2012 |
Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H, Boehm I, Groepper D, Reynolds CP, Stewart CF, Lock RB. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. Plos One. 7: e33894. PMID 22479469 DOI: 10.1371/Journal.Pone.0033894 |
0.383 |
|
| 2012 |
Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 1266-74. PMID 22315240 DOI: 10.1002/Pbc.24073 |
0.448 |
|
| 2012 |
Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ. Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatric Blood & Cancer. 59: 753-5. PMID 22315235 DOI: 10.1002/Pbc.23391 |
0.373 |
|
| 2012 |
Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel JA, Reynolds CP. Novel cell lines established from pediatric brain tumors. Journal of Neuro-Oncology. 107: 269-80. PMID 22120608 DOI: 10.1007/S11060-011-0756-5 |
0.394 |
|
| 2012 |
Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 59: 518-24. PMID 22102563 DOI: 10.1002/Pbc.23412 |
0.319 |
|
| 2012 |
Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 749-52. PMID 22052829 DOI: 10.1002/Pbc.23364 |
0.421 |
|
| 2012 |
Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatric Blood & Cancer. 58: 815-8. PMID 22052798 DOI: 10.1002/Pbc.23290 |
0.402 |
|
| 2012 |
Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 246-53. PMID 22012946 DOI: 10.1002/Pbc.23357 |
0.44 |
|
| 2012 |
Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 329-32. PMID 21922647 DOI: 10.1002/Pbc.23319 |
0.449 |
|
| 2012 |
Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 58: 636-9. PMID 21681929 DOI: 10.1002/Pbc.23167 |
0.444 |
|
| 2012 |
Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 916-23. PMID 21584937 DOI: 10.1002/Pbc.23176 |
0.449 |
|
| 2012 |
Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 200-9. PMID 21548007 DOI: 10.1002/Pbc.23016 |
0.411 |
|
| 2012 |
Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood & Cancer. 59: 185-8. PMID 21538821 DOI: 10.1002/Pbc.23154 |
0.429 |
|
| 2012 |
Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58: 191-9. PMID 21337679 DOI: 10.1002/Pbc.22935 |
0.45 |
|
| 2012 |
Gaines N, Nelius T, Gillen J, Rinard K, Lopez J, Hirsch J, Cobos E, Reynolds CP, Filleur S. Effect of PEDF on survival and in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer. Journal of Clinical Oncology. 30: 237-237. DOI: 10.1200/Jco.2012.30.15_Suppl.E15103 |
0.396 |
|
| 2012 |
Smith MA, Carol H, Evans K, Richmond J, Kang M, Reynolds CP, Chunduru S, Graham MA, Geier B, Kurmasheva R, Houghton PJ, Lock RB. Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNFα and Synergizes with TNFα in Vitro – A Report From the Pediatric Preclinical Testing Program (PPTP) Blood. 120: 3565-3565. DOI: 10.1182/Blood.V120.21.3565.3565 |
0.475 |
|
| 2012 |
Lopez-Barcons L, Kang MH, Maurer BJ, Reynolds CP. Abstract 2493: Enhanced activity of fenretinide/-LYM-X-SORBTM (4-HPR/LXS) oral powder in combination with ketoconazole and vincristine against recurrent neuroblastoma xenografts Cancer Research. 72: 2493-2493. DOI: 10.1158/1538-7445.Am2012-2493 |
0.335 |
|
| 2011 |
Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7093-104. PMID 21933888 DOI: 10.1158/1078-0432.Ccr-11-0578 |
0.321 |
|
| 2011 |
Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 443-53. PMID 21744473 DOI: 10.1002/Pbc.22921 |
0.4 |
|
| 2011 |
Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 606-11. PMID 21360651 DOI: 10.1002/Pbc.22877 |
0.443 |
|
| 2011 |
Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 57: 268-74. PMID 21360650 DOI: 10.1002/Pbc.22797 |
0.473 |
|
| 2011 |
Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 56: 595-603. PMID 21298745 DOI: 10.1002/Pbc.22741 |
0.461 |
|
| 2011 |
Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatric Blood & Cancer. 56: 239-49. PMID 20922763 DOI: 10.1002/Pbc.22801 |
0.416 |
|
| 2011 |
Carol H, Lock RB, Maris JM, Keir ST, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Morton CL, Smith PG, Thomas M, McDonald A, Houghton PJ, Smith MA. Abstract 740: Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924 Cancer Research. 71: 740-740. DOI: 10.1158/1538-7445.Am2011-740 |
0.472 |
|
| 2011 |
Wang J, Zhuo R, Drummond D, Reynolds CP, Kang MH. Abstract 5469: Pharmacokinetics and activity of nanoliposomal irinotecan (MM-398) against Ewings Sarcoma xenografts are superior to the conventional irinotecan formulation Cancer Research. 71: 5469-5469. DOI: 10.1158/1538-7445.Am2011-5469 |
0.381 |
|
| 2011 |
Houghton PJ, Lock RB, Carol H, Morton CL, Gorlick R, Kolb EA, Kier ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Smith MA. Abstract 5358: Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282 Cancer Research. 71: 5358-5358. DOI: 10.1158/1538-7445.Am2011-5358 |
0.461 |
|
| 2011 |
Tagde A, Reynolds CP. Abstract 2239: Buthionine sulfoximine enhanced melphalan cytotoxic activity against multiple myeloma cell lines Cancer Research. 71: 2239-2239. DOI: 10.1158/1538-7445.Am2011-2239 |
0.373 |
|
| 2011 |
Seidel D, Shibina A, Reynolds CP, Wels WS, Lode HN, Huebener N. Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing Cancer Research. 71: 1808-1808. DOI: 10.1158/1538-7445.Am2011-1808 |
0.4 |
|
| 2011 |
Shibina A, Seidel D, Somanchi S, Lode HN, Lee DA, Reynolds CP, Huebener N. Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing Cancer Research. 71: 1800-1800. DOI: 10.1158/1538-7445.Am2011-1800 |
0.431 |
|
| 2011 |
Reynolds CP, Kang MH, Carol H, Lock RB, Gorlick R, Kolb EA, Alexander D, Kurmasheva RT, Keir ST, Maris JM, Wu J, Houghton PJ, Smith MA. Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C106 |
0.449 |
|
| 2011 |
Houghton PJ, Maris JM, Keir ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Kurmasheva RT, Whiteman KR, Smith MA. Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C105 |
0.437 |
|
| 2010 |
Hadjidaniel MD, Reynolds CP. Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins. Molecular Cancer Therapeutics. 9: 3164-3174. PMID 21159604 DOI: 10.1158/1535-7163.Mct-10-0078 |
0.336 |
|
| 2010 |
Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 1224-6. PMID 20979180 DOI: 10.1002/Pbc.22355 |
0.435 |
|
| 2010 |
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. The New England Journal of Medicine. 363: 1313-23. PMID 20879880 DOI: 10.1056/Nejmoa1001527 |
0.349 |
|
| 2010 |
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 55: 668-77. PMID 20806365 DOI: 10.1002/Pbc.22576 |
0.442 |
|
| 2010 |
Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 1329-37. PMID 20740623 DOI: 10.1002/Pbc.22710 |
0.443 |
|
| 2010 |
Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 1126-33. PMID 20672370 DOI: 10.1002/Pbc.22712 |
0.444 |
|
| 2010 |
Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 55: 295-303. PMID 20582972 DOI: 10.1002/Pbc.22535 |
0.445 |
|
| 2010 |
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Molecular Cancer Therapeutics. 9: 1396-407. PMID 20423994 DOI: 10.1158/1535-7163.Mct-09-0604 |
0.388 |
|
| 2010 |
Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 54: 921-6. PMID 20166202 DOI: 10.1002/Pbc.22367 |
0.382 |
|
| 2010 |
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, et al. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatric Blood & Cancer. 54: 872-8. PMID 20127846 DOI: 10.1002/Pbc.22414 |
0.328 |
|
| 2010 |
Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9: 101-12. PMID 20053767 DOI: 10.1158/1535-7163.Mct-09-0952 |
0.421 |
|
| 2010 |
Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood & Cancer. 54: 707-15. PMID 20017204 DOI: 10.1002/Pbc.22352 |
0.431 |
|
| 2010 |
Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 54: 307-10. PMID 19856388 DOI: 10.1002/Pbc.22188 |
0.424 |
|
| 2010 |
Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract 5265: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor Cancer Research. 70: 5265-5265. DOI: 10.1158/1538-7445.Am10-5265 |
0.449 |
|
| 2010 |
Ghent MV, Kim Y, Jakimenko A, Reynolds CP. Abstract 5262: Resistance to fenretinide in neuroblastoma is associated with increased expression of sphingosine kinase and sphingosine-1-phosphate receptors and targeting sphingosine kinase reverses resistance Cancer Research. 70: 5262-5262. DOI: 10.1158/1538-7445.Am10-5262 |
0.334 |
|
| 2010 |
Wai DH, Wu D, Wing MR, Arceci RJ, Reynolds CP, Sorensen PH, Reamon GH, Milos PM, Lawlor ER, Buckley JD, Kapranov P, Triche TJ. Abstract 4087: Large intergenic noncoding RNAs associated with Ewing sarcoma family of tumors Cancer Research. 70: 4087-4087. DOI: 10.1158/1538-7445.Am10-4087 |
0.342 |
|
| 2010 |
Potratz J, Saunders D, Wai D, Reynolds CP, Buckley JD, Arceci RJ, Reaman GH, Triche TJ, Jürgens H, Pollak M, Sorensen PH. Abstract 3422: Synthetic lethal siRNA screening reveals novel modifiers of insulin-like growth factor-1 receptor (IGF1R) inhibitor activity in childhood sarcomas Cancer Research. 70: 3422-3422. DOI: 10.1158/1538-7445.Am10-3422 |
0.39 |
|
| 2009 |
Rosol M, Harutyunyan I, Xu J, Melendez E, Smbatyan G, Finlay JL, Krieger MD, Gonzalez-Gomez I, Reynolds CP, Nelson MD, Erdreich-Epstein A, Blüml S. Metabolism of orthotopic mouse brain tumor models. Molecular Imaging. 8: 199-208. PMID 19728974 DOI: 10.2310/7290.2009.00019 |
0.367 |
|
| 2009 |
Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 594-8. PMID 19554571 DOI: 10.1002/Pbc.21989 |
0.349 |
|
| 2009 |
Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 1255-63. PMID 19554570 DOI: 10.1002/Pbc.22056 |
0.31 |
|
| 2009 |
Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE. Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Research. 69: 4143-9. PMID 19435921 DOI: 10.1158/0008-5472.Can-08-3112 |
0.35 |
|
| 2009 |
Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53: 505-8. PMID 19418547 DOI: 10.1002/Pbc.21988 |
0.429 |
|
| 2009 |
Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatric Blood & Cancer. 53: 509-12. PMID 19418543 DOI: 10.1002/Pbc.21976 |
0.435 |
|
| 2009 |
Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research. 15: 1126-1132. PMID 19228717 DOI: 10.1158/1078-0432.Ccr-08-0144 |
0.314 |
|
| 2009 |
Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1290-6. PMID 19171709 DOI: 10.1200/Jco.2008.18.5918 |
0.313 |
|
| 2009 |
Heuston E, Farrar JE, Triche T, Buckley J, Sorensen P, Reynolds CP, Reaman G, Yegnasubramanian V, Arceci RJ. Selective and Titratable Effects On AML Genome Wide Methylation Patterning, Transcription and Clonogenicity Using Very Low Concentrations of 5-Aza-2'deoxycytidine. Blood. 114: 2385-2385. DOI: 10.1182/Blood.V114.22.2385.2385 |
0.313 |
|
| 2009 |
Houghton PJ, Maris JM, Courtright J, Friedman HS, Keir ST, Lock RB, Carol H, Kolb EA, Gorlick R, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C57 |
0.443 |
|
| 2008 |
Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, et al. Molecular characterization of the pediatric preclinical testing panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4572-83. PMID 18628472 DOI: 10.1158/1078-0432.Ccr-07-5090 |
0.323 |
|
| 2008 |
Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Journal of the National Cancer Institute. 100: 580-95. PMID 18398104 DOI: 10.1093/Jnci/Djn076 |
0.379 |
|
| 2008 |
Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 51: 42-8. PMID 18293383 DOI: 10.1002/Pbc.21535 |
0.433 |
|
| 2008 |
Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatric Blood & Cancer. 51: 34-41. PMID 18260120 DOI: 10.1002/Pbc.21508 |
0.413 |
|
| 2008 |
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1190-7. PMID 18260118 DOI: 10.1002/Pbc.21450 |
0.441 |
|
| 2008 |
Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 533-40. PMID 18223229 DOI: 10.1158/1078-0432.Ccr-06-2289 |
0.353 |
|
| 2008 |
Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1181-9. PMID 18085673 DOI: 10.1002/Pbc.21433 |
0.48 |
|
| 2008 |
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 1198-206. PMID 17914733 DOI: 10.1002/Pbc.21368 |
0.458 |
|
| 2008 |
Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 799-805. PMID 17635004 DOI: 10.1002/Pbc.21296 |
0.471 |
|
| 2008 |
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 992-1000. PMID 17554786 DOI: 10.1002/Pbc.21263 |
0.43 |
|
| 2008 |
Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 581-7. PMID 17457854 DOI: 10.1002/Pbc.21232 |
0.424 |
|
| 2008 |
Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50: 37-45. PMID 17420992 DOI: 10.1002/Pbc.21214 |
0.436 |
|
| 2007 |
Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Research. 67: 9346-55. PMID 17909043 DOI: 10.1158/0008-5472.Can-06-4508 |
0.377 |
|
| 2007 |
Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. The Journal of Clinical Investigation. 117: 2702-12. PMID 17710228 DOI: 10.1172/Jci30751 |
0.389 |
|
| 2007 |
Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Journal of the National Cancer Institute. 99: 1107-19. PMID 17623797 DOI: 10.1093/Jnci/Djm044 |
0.358 |
|
| 2007 |
Reynolds CP, Kang MH, Keshelava N, Maurer BJ. Assessing combinations of cytotoxic agents using leukemia cell lines. Current Drug Targets. 8: 765-71. PMID 17584032 DOI: 10.2174/138945007780830845 |
0.384 |
|
| 2007 |
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 110: 2057-2066. PMID 17536015 DOI: 10.1182/Blood-2007-03-080325 |
0.37 |
|
| 2007 |
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Research. 67: 3094-105. PMID 17409416 DOI: 10.1158/0008-5472.Can-06-3259 |
0.341 |
|
| 2007 |
Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Research. 67: 32-40. PMID 17210681 DOI: 10.1158/0008-5472.Can-06-0610 |
0.371 |
|
| 2007 |
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer. 49: 928-40. PMID 17066459 DOI: 10.1002/Pbc.21078 |
0.438 |
|
| 2007 |
Mohrbacher A, Gutierrez M, Murgo AJ, Kummar S, Reynolds CP, Maurer BJ, Groshen S, Vergara L, Kang MH, Yang AS. Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies. Blood. 110: 2581-2581. DOI: 10.1182/Blood.V110.11.2581.2581 |
0.305 |
|
| 2006 |
Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). Journal of Clinical Oncology. 24: 3423-3430. PMID 16849757 DOI: 10.1200/Jco.2005.03.9271 |
0.313 |
|
| 2006 |
Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1750-9. PMID 16551859 DOI: 10.1158/1078-0432.Ccr-05-2000 |
0.301 |
|
| 2006 |
Grupp SA, Cohn SL, Wall D, Reynolds CP. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatric Blood & Cancer. 46: 719-722. PMID 16429413 DOI: 10.1002/Pbc.20769 |
0.309 |
|
| 2006 |
Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study Journal of Clinical Oncology. 24: 500-506. PMID 16421427 DOI: 10.1200/Jco.2005.03.6400 |
0.324 |
|
| 2005 |
Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods in Molecular Medicine. 111: 335-50. PMID 15911989 DOI: 10.1385/1-59259-889-7:335 |
0.376 |
|
| 2005 |
Reynolds CP, Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods in Molecular Medicine. 110: 173-183. PMID 15901935 DOI: 10.1385/1-59259-869-2:173 |
0.316 |
|
| 2005 |
Grigoryan R, Keshelava N, Anderson C, Reynolds CP. In vitro testing of chemosensitivity in physiological hypoxia. Methods in Molecular Medicine. 110: 87-100. PMID 15901930 DOI: 10.1385/1-59259-869-2:087 |
0.386 |
|
| 2005 |
Yang B, Reynolds CP. Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent Clinical Cancer Research. 11: 2774-2780. PMID 15814660 DOI: 10.1158/1078-0432.Ccr-04-2382 |
0.344 |
|
| 2005 |
Sheard MA, Wu H, Asgharzadeh S, Keshelava N, Reynolds CP, Ye W, Groshen S, Metelitsa L, Seeger RC. Expression of TRAIL on Activated Human NK Cells Contributes to Cytotoxicity Against Human Neuroblastoma Cell Lines Journal of Immunotherapy. 28: 618. DOI: 10.1097/01.Cji.0000190965.88278.Cd |
0.329 |
|
| 2004 |
Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research. 64: 5415-5424. PMID 15289350 DOI: 10.1158/0008-5472.Can-04-0377 |
0.377 |
|
| 2004 |
Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatric Transplantation. 8: 56-66. PMID 15125707 DOI: 10.1111/J.1398-2265.2004.00216.X |
0.355 |
|
| 2004 |
Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Letters. 206: 169-80. PMID 15013522 DOI: 10.1016/J.Canlet.2003.08.034 |
0.416 |
|
| 2003 |
Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Letters. 197: 185-192. PMID 12880980 DOI: 10.1016/S0304-3835(03)00108-3 |
0.353 |
|
| 2002 |
Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. The Journal of Biological Chemistry. 277: 49531-7. PMID 12388538 DOI: 10.1074/Jbc.M209962200 |
0.309 |
|
| 2001 |
Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. Journal of Pediatric Hematology/Oncology. 23: 500-5. PMID 11878777 DOI: 10.1097/00043426-200111000-00007 |
0.335 |
|
| 2001 |
Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematology-Oncology Clinics of North America. 15: 867-910. PMID 11765378 DOI: 10.1016/S0889-8588(05)70256-2 |
0.334 |
|
| 2001 |
Hoon DS, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, Seeger RC. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. The American Journal of Pathology. 159: 493-500. PMID 11485908 DOI: 10.1016/S0002-9440(10)61721-X |
0.338 |
|
| 2000 |
Reynolds CP. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma Current Oncology Reports. 2: 511-518. PMID 11122886 DOI: 10.1007/S11912-000-0104-Y |
0.307 |
|
| 2000 |
Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Medical and Pediatric Oncology. 35: 659-62. PMID 11107141 DOI: 10.1002/1096-911X(20001201)35:6<659::Aid-Mpo38>3.0.Co;2-4 |
0.341 |
|
| 2000 |
Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. Journal of the National Cancer Institute. 92: 1897-909. PMID 11106681 DOI: 10.1093/Jnci/92.23.1897 |
0.36 |
|
| 2000 |
Chen R, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunology, Immunotherapy. 48: 603-612. PMID 10663607 DOI: 10.1007/S002620050008 |
0.341 |
|
| 2000 |
Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines Cancer Chemotherapy and Pharmacology. 45: 1-8. PMID 10647494 DOI: 10.1007/Pl00006736 |
0.365 |
|
| 1999 |
Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Experimental Cell Research. 246: 183-92. PMID 9882527 DOI: 10.1006/Excr.1998.4303 |
0.372 |
|
| 1998 |
Goldberg SS, Desantes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK. Engraftment after myeloablative doses of 131I- Metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma Medical and Pediatric Oncology. 30: 339-346. PMID 9589082 DOI: 10.1002/(Sici)1096-911X(199806)30:6<339::Aid-Mpo7>3.0.Co;2-F |
0.308 |
|
| 1998 |
Jong AY, Yu K, Zhou B, Frgala T, Reynolds CP, Yen Y. A simple and sensitive ribonucleotide reductase assay Journal of Biomedical Science. 5: 62-68. PMID 9570515 DOI: 10.1007/Bf02253357 |
0.316 |
|
| 1998 |
Seeger RC, Rosenblatt JD, Duerst RE, Reynolds CP, Villablanca JG, Hasenauer B, Feig SA. A Phase I study of human gamma interferon gene-transduced tumor cells in patients with neuroblastoma. Human Gene Therapy. 9: 379-90. PMID 9508055 DOI: 10.1089/Hum.1998.9.3-379 |
0.336 |
|
| 1996 |
Tomayko MM, Triche TJ, Reynolds CP. Human neuroblastoma cell lines regain catecholamine fluorescence when xenografted into athymic (nude) mice. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 14: 771-7. PMID 8960984 DOI: 10.1016/S0736-5748(96)00050-0 |
0.401 |
|
| 1995 |
Zwicker JI, Proffitt RT, Reynolds CP. A microcomputer program for calculating cell population doubling time in vitro and in vivo Cancer Chemotherapy and Pharmacology. 37: 203-210. PMID 8529279 DOI: 10.1007/Bf00688318 |
0.354 |
|
| 1994 |
Ungar DR, Hailat N, Strahler JR, Kuick RD, Brodeur GM, Seeger RC, Reynolds CP, Hanash SM. Hsp27 expression in neuroblastoma : correlation with disease stage Journal of the National Cancer Institute. 86: 780-784. PMID 8169976 DOI: 10.1093/Jnci/86.10.780 |
0.324 |
|
| 1993 |
Keim DR, Hailat N, Kuick R, Reynolds CP, Brodeur GM, Seeger RC, Hanash SM. PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors Clinical & Experimental Metastasis. 11: 83-90. PMID 8093685 DOI: 10.1007/Bf00880069 |
0.347 |
|
| 1992 |
Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Medical and Pediatric Oncology. 20: 307-11. PMID 1608352 DOI: 10.1002/Mpo.2950200407 |
0.306 |
|
| 1991 |
Sugimoto T, Ueyama H, Hosoi H, Inazawa J, Kato T, Kemshead JT, Reynolds CP, Gown AM, Mine H, Sawada T. Alpha-Smooth-Muscle Actin And Desmin Expressions In Human Neuroblastoma Cell Lines International Journal of Cancer. 48: 277-283. PMID 2019470 DOI: 10.1002/Ijc.2910480221 |
0.305 |
|
| 1991 |
Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatric Clinics of North America. 38: 393-424. PMID 2006084 DOI: 10.1016/S0031-3955(16)38084-1 |
0.346 |
|
| 1989 |
Lee BR, Hasemann DB, Reynolds CP. A digital image microscopy system for rare-event detection using fluorescent probes Cytometry. 10: 256-262. PMID 2653739 DOI: 10.1002/Cyto.990100304 |
0.311 |
|
| 1989 |
Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy and Pharmacology. 24: 148-54. PMID 2544306 DOI: 10.1007/Bf00300234 |
0.339 |
|
| 1981 |
Reynolds CP, Perez-Polo JR. Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell lines. Neuroscience Letters. 26: 151-5. PMID 6795547 DOI: 10.1016/0304-3940(81)90341-4 |
0.35 |
|
| 1981 |
Reynolds CP, Smith RG, Frenkel EP. The diagnostic dilemma of the "small round cell neoplasm": catecholamine fluorescence and tissue culture morphology as markers for neuroblastoma. Cancer. 48: 2088-2094. PMID 6271391 DOI: 10.1002/1097-0142(19811101)48:9<2088::Aid-Cncr2820480929>3.0.Co;2-U |
0.331 |
|
| 1975 |
Reynolds CP, Pérez-Polo JR. Human neuroblastoma: Glial induced morphological differentiation. Neuroscience Letters. 1: 91-7. PMID 19604759 DOI: 10.1016/0304-3940(75)90051-8 |
0.324 |
|
| Show low-probability matches. |